Loading
A phase 3 trial of Trastuzumab emtansine in her2-positive breast cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer is a phase 3 interventional study registered as NCT06313086 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 442 participants planned, started 2024-03-13 and due to reach its primary completion in 2025-12. Interventions recorded: DP303c, trastuzumab emtansine. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).